凯普生物
(300639)
| 流通市值：39.38亿 | | | 总市值：40.08亿 |
| 流通股本：6.35亿 | | | 总股本：6.47亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,104,453,848.02 | 850,628,909.69 | 606,634,951.95 | 302,111,598.82 |
| 营业收入 | 1,104,453,848.02 | 850,628,909.69 | 606,634,951.95 | 302,111,598.82 |
| 二、营业总成本 | 1,098,029,672.79 | 780,563,653.22 | 519,847,600.2 | 269,430,605.18 |
| 营业成本 | 430,417,261.88 | 326,174,363.6 | 211,457,332.24 | 115,855,670.18 |
| 税金及附加 | 10,325,243.55 | 6,683,866.61 | 3,859,012.01 | 2,042,515.44 |
| 销售费用 | 279,122,721.6 | 158,247,861.81 | 102,069,031.45 | 73,284,309.3 |
| 管理费用 | 253,356,020.06 | 183,281,249.69 | 124,037,189.95 | 58,583,144.06 |
| 研发费用 | 136,321,683.55 | 102,355,167.92 | 71,154,158.3 | 37,746,736.63 |
| 财务费用 | -11,513,257.85 | 3,821,143.59 | 7,270,876.25 | -18,081,770.43 |
| 其中:利息费用 | 4,944,844.45 | 3,846,498.98 | 2,465,423.6 | 5,675,130.84 |
| 其中:利息收入 | 33,502,146.17 | 15,744,025.98 | 11,755,848.23 | 1,620,282.83 |
| 加:公允价值变动收益 | -1,834.96 | -8,733.24 | -5,394.06 | -2,825.46 |
| 加:投资收益 | 13,944,049.55 | 10,769,331.25 | 11,574,699.13 | -71,911.74 |
| 资产处置收益 | 7,060,528.61 | 6,772,244.05 | 6,804,852.35 | 16,201.46 |
| 资产减值损失(新) | -9,981,979.44 | 22,735,306.55 | 16,334,871.99 | 2,981,387.44 |
| 信用减值损失(新) | 10,281,542.3 | 5,179,976.92 | -7,063,605.09 | 16,173,226.19 |
| 其他收益 | 14,873,242.59 | 12,275,637.69 | 10,597,737.37 | 8,866,768.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 42,599,723.88 | 127,789,019.69 | 125,030,513.44 | 60,643,840.39 |
| 加:营业外收入 | 587,648.52 | 495,606.21 | 171,958.12 | 67,507.02 |
| 减:营业外支出 | 6,371,284.45 | 7,054,218.05 | 4,081,480.56 | 1,737,255.08 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 36,816,087.95 | 121,230,407.85 | 121,120,991 | 58,974,092.33 |
| 减:所得税费用 | -31,698,359.18 | 4,556,016.71 | 31,763,046.27 | 12,667,364.84 |
| 六、净利润 | 68,514,447.13 | 116,674,391.14 | 89,357,944.73 | 46,306,727.49 |
| 持续经营净利润 | 68,514,447.13 | 116,674,391.14 | 89,357,944.73 | 46,306,727.49 |
| 归属于母公司股东的净利润 | 140,472,219.75 | 172,102,971.56 | 122,842,813.31 | 65,353,876.62 |
| 少数股东损益 | -71,957,772.62 | -55,428,580.42 | -33,484,868.58 | -19,047,149.13 |
| (一)基本每股收益 | 0.25 | 0.26 | 0.19 | 0.15 |
| (二)稀释每股收益 | 0.25 | 0.26 | 0.19 | 0.15 |
| 八、其他综合收益 | 17,418,432.85 | 19,984,901.21 | 24,838,801.65 | -27,057,644.22 |
| 归属于母公司股东的其他综合收益 | 17,418,432.85 | 19,984,901.21 | 24,838,801.65 | -27,057,644.22 |
| 九、综合收益总额 | 85,932,879.98 | 136,659,292.35 | 114,196,746.38 | 19,249,083.27 |
| 归属于母公司股东的综合收益总额 | 157,890,652.6 | 192,087,872.77 | 147,681,614.96 | 38,296,232.4 |
| 归属于少数股东的综合收益总额 | -71,957,772.62 | -55,428,580.42 | -33,484,868.58 | -19,047,149.13 |
| 公告日期 | 2024-04-24 | 2023-10-26 | 2023-08-31 | 2023-04-25 |
| 审计意见(境内) | 标准无保留意见 | | | |